ARCHIVES

Genentech: ODAC Lacks Expertise, Impartiality; FDA: Company’s Proposal Unscientific

This article is from The Cancer Letter archive.

Vol. 37 No. 32 | August 12, 2011

Download PDF Visit The Full Archive

Related Articles

Moloney Convinces Most NCAB Members Of Virus Program Value, Shubik Only Dissenter

October 15, 1976

Drug Development: Herceptin Associated with 15 Deaths, Genentech Says

May 12, 2000

From One Competitive Market to Another: UC San Diego Stakes A Claim in Las Vegas

January 27, 2012

Harkin, Hatfield Introduce Medical Research Trust Fund

March 4, 1994

NCI prepares for third hearing on conflicts of interest.

June 18, 2004

Medicare Coverage For Clinical Trials Tops NBCC Agenda

January 30, 1998